Dilemma, causes and countermeasures of global health governance: taking COVID-19 Vaccines Global Access Facility as an example.
10.3760/cma.j.cn112338-20211216-00987
- Author:
An Ying BAI
1
;
Bo ZHANG
2
;
Yu JIANG
1
;
You Lin QIAO
2
Author Information
1. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Center for Global Health, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
COVID-19/prevention & control*;
COVID-19 Vaccines;
Global Health;
Humans;
SARS-CoV-2;
Vaccines
- From:Chinese Journal of Epidemiology
2022;43(4):483-487
- CountryChina
- Language:Chinese
-
Abstract:
The pandemic of COVID-19 threatens the health and safety of the people all over the world. COVID-19 vaccine is the key public product to establish population immune barrier and achieve the global contain of the pandemic. The World Health Organization, the Global Alliance for Vaccines and Immunization and the Coalition for Epidemic Preparedness Innovations established COVID-19 Vaccines Global Access Facility (COVAX) in 2020, aiming to enable the fair access to COVID-19 vaccine by all countries in the world, especially the low- and middle-income countries. Although COVAX has facilitated the production and research of COVID-19 vaccine by coordinating the global supply chain, the implementation of COVAX is still facing many difficulties in financing, implementation and the awareness of public, revealing the problems of global health governance. Taking COVAX as an example, this paper analyzes the difficulties faced by global health governance and explore the underlying causes, so as to suggest feasible short and long-term paths for China's participation in global governance.
